Introduction
The emergence and spread of antibiotic resistance is a global health priority. The b-lactamases provide a major defense mechanism for Gram-negative bacteria. These enzymes have coevolved with the development of new b-lactam antibiotics by modifying their substrate spectrum and spreading to pathogens that previously lacked resistance enzymes. The newer b-lactamases include extended-spectrum (ESBL), plasmid-mediated AmpC enzymes and carbapenem-hydrolyzing enzymes (carbapenemases). More than 20 different plasmid-mediated AmpC b-lactamases have been identified. Characteristically, AmpC b-lactamases result in resistance to cephamycins (cefotetan, cefoxitin) and oxyimino-blactams (cefotaxime, ceftriaxone, ceftazidime), antibiotics with an oxyimino-side chain designed to block the action of b-lactamases. 1 The AmpC b-lactamases are usually refractory to inhibition by clavulanic acid. Infections with organisms harboring AmpC-type plasmid-borne cephalosporinases are being encountered with increasing frequency among adults, but to date have not been reported in neonates. Thus, we were surprised to isolate an Escherichia coli possessing a transferable CMY-2 family b-lactamase from the blood and cerebrospinal fluid (CSF) of a newborn. The limited experience with newer antibiotic options and pharmacokinetics in neonates poses a formidable challenge.
Case presentation
Twin A was delivered at 33 weeks gestation by vacuum-assisted low forceps vaginal delivery after 3 h of ruptured membranes. Apgar scores were 9 at 1 and 5 min. Initial evaluation revealed 1880 g, appropriate for gestational age newborn with a normal examination. Because of the premature delivery, blood and urine cultures were obtained and the newborn received ampicillin and cefotaxime intravenously for 48 h; cultures yielded no growth. On day 4 of life, temperature instability and seizure activity were observed. Examination yielded no additional findings. The baby was intubated for airway protection. A blood culture and CBC were obtained and a lumbar puncture was performed (Table 1) . Ampicillin and cefotaxime were resumed. Within 4 h, the blood culture revealed growth of Gram-negative bacilli, which were also detected on Gram stain of the CSF. Gentamicin was added to the antibiotic regimen. The bacteria were subsequently identified as E. coli. The initial broth microdilution antimicrobial susceptibility results (Microscan) for both isolates were as follows: resistant to cefazolin, cefoxitin and cefuroxime, susceptible to cefotetan, cefotaxime, cefepime, piperacillin-tazobactam, gentamicin and meropenem, but intermediate to ceftriaxone. Given the discordant susceptibility to the third-generation cephalosporins (cefotaxime and ceftriaxone), the possibility of an Amp C mutation was considered and the regimen was changed to meropenem and gentamicin. Repeat CSF culture obtained 4 days after initiation of antibiotics again grew E. coli. The antimicrobial susceptibility results for this isolate were identical. A magnetic resonance imaging (MRI) of the brain on day of life 13 (8 days into antibiotic treatment) revealed subdural empyema, leptomeningeal enhancement and enhancing septations suggestive of abscess formation. Cefepime was added to the regimen. A subsequent CSF culture obtained on day 14 of life was sterile. Gentamicin was discontinued after 2 weeks and the infant completed a 2-month course with cefepime and meropenem administered intravenously through a central line. The infant improved with resolution of the subdural empyema and abscesses by MRI. Brainstem auditoryevoked responses were normal at 3 weeks and 2 months of age. Neither the mother nor Twin B developed any signs or symptoms of infection. The mother, who was employed as a medical secretary in the community, did not have close contact with patients, denied being ill during pregnancy and did not receive any antibiotics. Except for twin gestation, no other reason for premature delivery was identified. The newborn screen for galactosemia was negative.
The isolates carried a large plasmid (>100 kb) that transferred ampicillin resistance to E. coli DH5-a and expressed a single blactamase with a pI of 9.0 that was inhibited by aztreonam, indicating a member of the AmpC family. 2, 3 The initial polymerase chain reaction (PCR) reaction generated a 0.5 kb fragment that, when sequenced, had 100% identity to the CMY-2 family of AmpC b-lactamases. 4 To confirm the gene identity, a second PCR reaction was conducted using newly designed primers that extended outside the coding region (forward and reverse primers: CMY-2 F1 (5 0 -GCTAAATTTAACCGTTTGTCAACACGG-3 0 ) and CMY-2 R1 (5 0 -ATGCGCATGGGATTTTCCTTGC-3 0 ). A single band of B1.2 kb was observed in four separate reactions. The resulting sequence had 100% homology to several CMY-2 plasmids, both from Salmonella spp. in the US (AY581205 to AY5812057) and Taiwan (AY899924 to AY899927), and also to a Klebsiella pneumoniae plasmid (X91840).
Discussion
A plasmid-mediated b-lactamase indistinguishable from the chromosomal AmpC enzyme of E. coli was first described in a strain of Proteus. mirabilis in 1976. 5 Subsequently, more than 20 different plasmid-mediated AmpC b-lactamases have been reported. 6 CMY-2 is the most prevalent. In the United States, 3 to 4% of Klebsiella pneumoniae and Klebsiella oxytoca isolates harbor the genome encoding for plasmid-mediated AmpC enzymes.
7 CMY-2 is also responsible for increasing resistance in Salmonella isolates. 8, 9 The source of the resistant bacteria in this neonate is unknown. Review of the prenatal history did not reveal any risk factors for colonization or infection with an antibioticresistant organism. Although the mother is employed as a secretary in a community medical office, she had no significant contact with patients and had not received antibiotics during the course of the pregnancy or during the delivery. There was no clinical evidence for chorioamnionitis. The possibility of nosocomial acquisition including the instrumentation associated with the delivery cannot be excluded.
E. coli is currently the most frequently isolated pathogen in early-onset sepsis and the most common cause of neonatal meningitis in the newborn period, particularly in very low birth weight preterm infants with increasing incidence in low birth weight as well as appropriate for gestational age infants. 10 In a recent report from the National Institute of Child Health and Human Development Neonatal Research Network, E. coli accounted for 41% of early-onset sepsis in very low birth weight preterm infants. Although 77% of the isolates were resistant to ampicillin, only one was resistant to cephalosporins; the mechanism of resistance was not described. 11 The predominance of Gram-negative bacteria in early-onset neonatal infections has been attributed to the significant decline in the rate of group B streptococcal infection with guidelines recommending universal screening at 35 or more weeks of gestation and intra-partum antibiotics for colonized women. 12 The optimal treatment for AmpC-producing strains is unclear. Although initially cefepime was thought to be appropriate, in vitro activity of cefepime in high inoculum minimum inhibitory concentration tests may be reduced. Although the inoculum effect is an in vitro phenomenon, clinical significance cannot be excluded. 13 AmpC-expressing bacteria are usually susceptible to carbapenems; however, diminished porin protein expression leading to reduced carbapenem susceptibility has been identified. 14 Carbapenem resistance among strains of K. pneumoniae resulting from a combination of a plasmid-mediated AmpC enzyme (ACT-1) and the loss of an outer membrane protein has been reported. 15 The situation for neonatal meningitis is even more complex where central nervous system penetration and pharmacokinetic data are limited. Carbapenems with activity against AmpC b-lactamases include imipenem, meropenem and the newer agent, ertapenem. 16 Imipenem-cilastatin is not recommended for meningitis because of AmpC-resistant E. coli in neonates E Fakioglu et al early reports of drug-associated seizures. However, meropenem offers an efficacy and safety profile similar to that of cefotaxime for bacterial meningitis in infants and children. 17 Thus, given the experience with meropenem and the concerns for possible high inoculum resistance with cefepime, meropenem and gentamicin were initially prescribed when AmpC resistance was suspected. However, because of the delay in sterilizing the CSF, cefepime was added to the regimen. Cefepime is safe and therapeutically equivalent to cefotaxime for management of bacterial meningitis in infants and children. 18 Other possible explanations for the delay in CSF sterilization include sequestration of the organism in abscesses and subdural empyemas. Because the neonate responded to the combination of meropenem and cefepime, we elected to continue this regimen. There is limited in vitro data to support the use of two b-lactams to achieve synergistic killing of multi-drug-resistant pathogens' preferential binding to different penicillin-binding proteins possibly explaining the interactions. 19 There are no Clinical Laboratory Standards Institute (CLSI) recommendations for detecting AmpC enzymes or carbapenemases. The presence of cefoxitin or cefotetan resistance along with oxyimino-b-lactam resistance raises the suspicion of an AmpC-type enzyme. Discordant susceptibility to third-generation cephalosporins may also be observed, as was true in this case. Thus, it is imperative that clinicians have a high index of suspicion when cephalosporin susceptibility patterns are inconsistent as it is likely that AmpC b-lactamases are underreported. Development of better microbiology screening tests to rapidly detect resistance is warranted.
